论文部分内容阅读
应用三氧化二砷注射液治疗7例复发急性早幼粒细胞白血病（APL），复发时间平均为完全缓解（CR）后18（3～30）个月。7例均获再CR，达CR时总剂量10ml×42支（3～62支）。治疗中出现不同程度白细胞升高，达高峰时间14～25天，峰值22．9～255×109／L，均有轻度恶心、纳差，偶有轻度骨髓抑制，ALT及BIL－T轻度升高。随访2～17个月均存活．其中3倒在CR时PML／RARα基因（RT－PCR法）仍阳性。三氧化二砷毒副作用小，疗效好，对于复发及全反式维甲酸（ATRA）再诱导无效的APL尤显其优越性，但关于缓解后PML／RARα残留病灶的变化尚需积累更多病例追踪评判。
Seven patients with relapsed acute promyelocytic leukemia (APL) were treated with arsenic trioxide injection. The average time to relapse was 18 (3 to 30) months after complete remission (CR). All patients received CR in 7 cases and the total dose was 10 ml x 42 (3 to 62). Treatment with varying degrees of leukocytosis, peaking time 14 to 25 days, peak 22.9 ~ 255 × 109 / L, both mild nausea, anorexia, occasional mild myelosuppression, ALT and BIL-T light Increased. Follow-up 2 to 17 months all survived. Among them, PML/RARα gene (RT-PCR method) was still positive when it fell to CR. The arsenic trioxide has less toxic and side effects and good curative effect. It is particularly advantageous for relapse and APL that is not effective for reinduction of all-trans retinoic acid (ATRA). However, more cases need to be accumulated to track and evaluate the changes of residual PML/RARα residual lesions after remission.